- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02531464
Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer
Effectiveness of a Multi-faceted Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer
Studieoversikt
Detaljert beskrivelse
Lung cancer may cause severe distress not only in patients but also in their family caregivers (FCs), with a direct impact on quality of life (QoL). Distress can be higher in FCs than in patients. Results from a recent study on continuity of cancer care conducted by the investigators support these findings, as a significantly larger proportion of FCs than patients reported high levels of anxiety and distress early after the diagnosis of lung cancer and this difference remained after 6 and 12 months. Several cancer centers have implemented systematic distress screening program during the care trajectory, but they target only patients without extending it to FCs. This study aims to implement and assess the effectiveness of a multi-faceted intervention to improve supportive care for FCs of patients with lung cancer.
Specific objectives:
To assess the effectiveness of the intervention on:
1.1 Caregivers' outcomes: distress (primary outcome), anxiety, depression, QoL, needs, burden, perception of health, preparedness in caregiving, perceived social support 1.2 Patients' outcomes: distress, anxiety, depression, QoL, pain and other symptom relief 1.3 Care process outcomes: FCs and patients' utilization of services
- To further document and describe:
2.1 In the experimental group: FCs perceived usefulness of the intervention and perceived effect on distress/QoL 2.2 In the oncology team: perceived usefulness of the intervention and perceived effect on their practice/organization of care Methods: An experimental design is used to test the intervention during 9 months in a pulmonary oncology clinic in Quebec City where a distress screening tool is implemented for cancer patients (but not for FCs). A total of 120 FCs of patients newly diagnosed with a non-surgical lung cancer, followed at the clinic have been randomly assigned to either the intervention (experimental group N=60) or to usual care (control group N=60). Considering a 20% withdrawal rate (due to death or severe deterioration of patients' condition), this sample size allows to detect a 33% difference in distress scores between the two groups, with an estimated baseline distress score (with the HADS) of 13.7±7 (range 0-42), a 5% alpha error and a power of 80%. The intervention comprises 3 components: 1) systematic distress screening and problems assessment of FCs at their relative's cancer diagnosis and then, every 2 months for a maximum of 9 months; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs who have reported a high level of distress (score ≥ 4 on the distress thermometer, which indicates a need for intervention), or who have mentioned needing help. In both groups, outcomes related to FCs and to care processes are measured with validated tools at baseline and every 3 months, for a maximum of 9 months. Measures are taken at the same intervals with patients since their physical and mental health may influence FCs' distress. Individual interviews with 12 FCs are planned to assess the usefulness of the intervention and its effect on their QoL. Interviews with the pivot nurses in oncology will document their satisfaction regarding the intervention and its effect on their practice.
Relevance. This translational study aims to assess the effectiveness of an intervention that transfers into practice the main recommendations of governmental authorities and experts regarding integrated care to globally improve cancer supportive care. It has the potential to make a significant impact on the burden of disease for FCs and to improve their quality of care. If proven effective, the conditions of success of this intervention could be replicated in other settings and for other types of cancer.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Quebec, Canada, G1V 4G5
- Institut universitaire de cardiologie et pneumologie de Québec (IUCPQ)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Relative identified by patients diagnosed with inoperable lung cancer as their principal family caregiver; having a family physician
Exclusion Criteria:
- Cognitive disorder
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Experimental: supportive care
Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
|
Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
|
Ingen inngripen: Control: usual care
In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) .
The PNO screens patients for distress and assesses their needs.
She does a bio-psycho-social comprehensive evaluation and may provide help and information.
She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory.
However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them.
If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in the mean score of distress (Hospital Anxiety Depression Scale)
Tidsramme: Baseline, after 3, 6 and 9 months
|
Measured by the Hospital Anxiety Depression Scale (HADS)
|
Baseline, after 3, 6 and 9 months
|
Change in the mean score of distress (Psychological distress scale used in the Quebec Health Survey)
Tidsramme: Baseline, after, 3, 6 and 9 months
|
Measured by the Psychological distress scale used in the Quebec Health Survey
|
Baseline, after, 3, 6 and 9 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in the preparedness for Caregiving (8-item validated instrument)
Tidsramme: Baseline, after 3, 6 and 9 months
|
8-item validated instrument measuring the perceived readiness for multiple domains of the caregiving role (providing physical care, emotional support, setting up in-home support services and dealing with the stress of caregiving); the scale varies from 0 to 4
|
Baseline, after 3, 6 and 9 months
|
Change in the caregiver's Burden Scale in End of Life Care
Tidsramme: Baseline, after 3, 6 and 9 months
|
16-item instrument validated with FCs who assist cancer patients in palliative care; the scale varies from 1 to 4
|
Baseline, after 3, 6 and 9 months
|
Change in the family caregiver needs (Home Caregiver Need Survey)
Tidsramme: Baseline, after 3, 6 and 9 months
|
Measured by the Home Caregiver Need Survey, a 25-item tool covering informational, practical, emotional and spiritual needs.
For each need, FCs indicate, on a 0 to 4 scale, its perceived importance and how well it is satisfied
|
Baseline, after 3, 6 and 9 months
|
Change in the family caregiver quality of life ( City-of-Hope Quality of Life Scale-Family Version)
Tidsramme: Baseline, after 3, 6 and 9 months
|
Measured by the City-of-Hope Quality of Life Scale-Family Version, a 37-item validated instrument that assesses 4 quality of life domains (physical, psychological, social and spiritual), with questions using a 0-10 scale; only the 4 items related to the general assessment of each quality of life domain will be used
|
Baseline, after 3, 6 and 9 months
|
Variation in service and health care resource utilization
Tidsramme: Baseline, after 3, 6 and 9 months
|
FCs will report the number of visits to their family physician and to any other health/psychosocial professional, meetings to support groups, use of community resources (volunteer services, respite, help for housework, etc.), use of sick leave, and prescription of sleeping pills, anxiolytic or antidepressant medications
|
Baseline, after 3, 6 and 9 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Michele Aubin, MD, PhD, Laval University
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FRQS-30740
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Lungekreft
-
Yonsei UniversityFullført
-
Novartis PharmaceuticalsFullførtNevroendokrine svulster | Avansert NET av GI Origin | Advanced NET of Lung OriginForente stater, Colombia, Italia, Taiwan, Storbritannia, Belgia, Tsjekkia, Tyskland, Japan, Saudi-Arabia, Canada, Nederland, Spania, Korea, Republikken, Libanon, Østerrike, Kina, Hellas, Sør-Afrika, Thailand, Ungarn, Tyrkia, Polen, Slov... og mer
-
The Cleveland ClinicTilbaketrukketOne Lung Ventillation (OLV) | To lungeventilasjon (TLV) | Positivt End Expiratory Pressure (PEEP) | Null sluttekspirasjonstrykk (ZEEP)
-
Assiut UniversityHar ikke rekruttert ennåLungekreft | Lungeskade | Bleb Lung
-
RenJi HospitalRekrutteringMultiple Synchronous Lung Cancers (MSLC)Kina
-
Poitiers University HospitalFullførtEndobronchial Transbronchial Needle Aspiration Lung Cancer Procore
-
University of LorraineFullførtBare barn | Spontan pneumothorax | Idiopatisk pneumotoraks | Bleb LungFrankrike
-
AHS Cancer Control AlbertaCross Cancer InstituteFullførtOmfattende Stage Small Cel Lung CancerCanada
-
Damascus UniversityUniversity Children's HospitalFullførtEsophageal atresi | One Lung Ventilation OLV | Hydrocystoma | Pneumonektomi | Pleura; AbscessDen syriske arabiske republikk
-
Ministry of Health, Saudi ArabiaHar ikke rekruttert ennåLuftveissykdom | Prematuritet | Ventilator Lung; Nyfødt
Kliniske studier på Supportive care
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRekrutteringPlasmacelleleukemi | Residiverende/refraktært myelomatoseKina
-
Bellicum PharmaceuticalsSuspendertHER2-positiv brystkreft | HER2-positiv magekreft | Solid svulst, voksen | HER-2 genamplifikasjon | HER-2 Protein OverekspresjonForente stater
-
Zhejiang UniversityCarbiogene Therapeutics Co. Ltd.Har ikke rekruttert ennåAvansert hepatocellulært karsinomKina
-
Nexcella Inc.Har ikke rekruttert ennåLettkjede (AL) amyloidoseForente stater
-
Second Affiliated Hospital, School of Medicine,...RekrutteringTilbakefallende og refraktær B-celle lymfomKina
-
Hebei Senlang Biotechnology Inc., Ltd.RekrutteringLymfom | Multippelt myelom | Akutt lymfatisk leukemiKina
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...TilbaketrukketAkutt lymfatisk leukemi | Non-hodgkin lymfomForente stater
-
Nanjing IASO Biotechnology Co., Ltd.Ruijin HospitalRekrutteringPlasmacelleleukemi | Residiverende/refraktært myelomatoseKina
-
Zhejiang UniversityYake Biotechnology Ltd.Har ikke rekruttert ennåAkutt myeloid leukemiKina
-
University of California, San FranciscoTilbaketrukketLymfom | Leukemi | Plasmacelledyskrasi